- Home
- PLSE vs NRIX Comparison
PLSE vs NRIX Comparison
Compare PLSE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | NRIX |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLSE | NRIX |
|---|---|---|
| Price | $25.33 | $14.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $22.00 | ★ $30.50 |
| AVG Volume (30 Days) | 366.1K | ★ 961.1K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $12.56 | $8.20 |
| 52 Week High | $28.53 | $22.50 |
Technical Indicators
Market Signals| Indicator | PLSE | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 32.11 |
| Support Level | $17.58 | $11.67 |
| Resistance Level | $26.30 | $17.06 |
| Average True Range (ATR) | 1.62 | 0.90 |
| MACD | -0.05 | -0.26 |
| Stochastic Oscillator | 28.60 | 3.88 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.